December ANDA Rush Is Largest In Two Years
FDA Reports Highest Monthly Total Since September 2017
Executive Summary
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
You may also be interested in...
ANDA Approval Records Will End As US FDA Mops Up Backlog
CDER Director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.
Generic Drug Approvals In US Off To Slow Start In FY 2020
US FDA reports another low tally of full approvals in October, but stakeholders are not worried given the agency's history of record-breaking totals year over year.
Generic Drug Application Submission Downturn Continued In June
Approvals also plummeted, but US FDA remains on a record-breaking pace.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Generics Bulletin?
Request a free trial today!
Register for our free email digests:
Register for our free email digests: